Evidence map›Paper›PMID 27806705›Full record

ReviewBMC medicine2016

Neuroimaging in vascular cognitive impairment: a state-of-the-art review.

Wolf-Dieter Heiss, Gary A Rosenberg, Alexander Thiel, Rok Berlot, Jacques de Reuck

Open access · goldAbstract readReview
In one paragraph

Review in BMC medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Stroke and dementia risk: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Pooled it
  2. Guideline
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 5 countries.

Wolf-Dieter HeissMax Planck Institute for Metabolism Research, Gleueler str. 50, D-50931, Cologne, Germany. wdh@sf.mpg.de.
Gary A RosenbergDepartment of Neurology, UNM Memory and Aging Center, MSC 11 6035, University of New Mexico, Albuquerque, NM, 87131, USA.
Alexander ThielDepartment of Neurology & Neurosurgery, McGill University at SMBD Jewish General Hospital and Lady Davis Institute for Medical Research, Montreal, H3T 1E2, Québec, Canada.
Rok BerlotDepartment of Neurology (R.B.), University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.
Jacques de ReuckINSERM U1171, Degenerative and Vascular Cognitive Disorders, Université Lille 2, Lille, France.
Jewish General Hospital · CALjubljana University Medical Centre · SIMax Planck Institute for Metabolism Research · DEUniversité de Lille · FRUniversity of New Mexico Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imaging is critical in the diagnosis and treatment of dementia, particularly in vascular cognitive impairment, due to the visualization of ischemic and hemorrhagic injury of gray and white matter. Magnetic resonance imaging (MRI) and positron emission tomography (PET) provide structural and functional information. Clinical MRI is both generally available and versatile - T2-weighted images show infarcts, FLAIR shows white matter changes and lacunar infarcts, and susceptibility-weighted images reveal microbleeds. Diffusion MRI adds another dimension by showing graded damage to white matter, making it more sensitive to white matter injury than FLAIR. Regions of neuroinflammatory disruption of the blood-brain barrier with increased permeability can be quantified and visualized with dynamic contrast-enhanced MRI. PET shows metabolism of glucose and accumulation of amyloid and tau, which is useful in showing abnormal metabolism in Alzheimer's disease. Combining MRI and PET allows identification of patients with mixed dementia, with MRI showing white matter injury and PET demonstrating regional impairment of glucose metabolism and deposition of amyloid. Excellent anatomical detail can be observed with 7.0-Tesla MRI. Imaging is the optimal method to follow the effect of treatments since changes in MRI scans are seen prior to those in cognition. This review describes the role of various imaging modalities in the diagnosis and treatment of vascular cognitive impairment.

Indexed as

Cognitive DysfunctionDementia, VascularFemaleHumansMagnetic Resonance ImagingMaleNeuroimagingPositron-Emission TomographyCerebral small vessel diseaseCTMolecular imagingMRINeuroimagingPETVascular cognitive impairment

Identifiers

PMID27806705
PMCPMC5094143
OpenAlexW2547093728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.